Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation

    loading  Checking for direct PDF access through Ovid

Abstract

Plasma cell dyscrasias (PCD) are a spectrum of diseases characterized by clonal proliferation of plasma cells secreting a monoclonal immunoglobulin. Although considered an incurable disease, a combination of autologous stem cell transplant with novel therapies, including lenalidomide, has improved the overall and progression-free survival of these patients. Renal impairment is an important complication of the disease that, in some cases, progresses to end-stage renal disease. Due to the characteristics of PCD, traditionally these patients have not been candidates for renal transplantation. However, treatment improvement allows a reconsideration of this perception, especially in younger patients with good performance status and treatment response. We report two cases of patients diagnosed with PCD undergoing renal transplantation after autologous stem cell transplantation, both cases under treatment with lenalidomide. We also report their perioperative management and their outcome.

Related Topics

    loading  Loading Related Articles